1 hr. ago
Apple (NASDAQ: AAPL) is recognized as one of the world's most elite businesses. And as a result of its success, investors have profited immensely. The consumer discretionary stock has soared 1,070% in the past decade (as of Oct. 2).
But the company's capital allocation policy also favors investors in another minor way, one that brings in an income stream. Here's how many Apple shares you'd need to make $10,000 in yearly dividends.
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ****** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Apple currently pays a dividend that totals $1.08 per share on an annual basis. This means that investors would need to own 9,259 shares to generate $10,000 in yearly income. At the current stock price of $331.22, investors must fork over almost $3.1 million to buy enough shares.
Clearly, Apple isn't a compelling dividend stock. Its dividend yield is extremely low at 0.32%. However, the payout has grown by 89% in the past 10 years.
#investors #Stock #income #yearly
But the company's capital allocation policy also favors investors in another minor way, one that brings in an income stream. Here's how many Apple shares you'd need to make $10,000 in yearly dividends.
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ****** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Apple currently pays a dividend that totals $1.08 per share on an annual basis. This means that investors would need to own 9,259 shares to generate $10,000 in yearly income. At the current stock price of $331.22, investors must fork over almost $3.1 million to buy enough shares.
Clearly, Apple isn't a compelling dividend stock. Its dividend yield is extremely low at 0.32%. However, the payout has grown by 89% in the past 10 years.
#investors #Stock #income #yearly
13 hours ago
Anson Williams has a very important message for baby boomers.
The 77-year-old Happy Days star posted a shirtless bathroom mirror selfie to Instagram on Oct. 3. He is seen smiling and flexing one arm in the photo.
He captioned the post, "My yearly reminder to every Boomer: NEVER let anyone diminish us because of our age."
"I'm 77. More creative, healthier, busier, more curious — and more alive than I was at 40," the actor wrote. "Why? A partner who sees the best in me. Good lovin.'"
Photo credit: OConnor / AFF-USA.com / MEGA
#happy #mega
The 77-year-old Happy Days star posted a shirtless bathroom mirror selfie to Instagram on Oct. 3. He is seen smiling and flexing one arm in the photo.
He captioned the post, "My yearly reminder to every Boomer: NEVER let anyone diminish us because of our age."
"I'm 77. More creative, healthier, busier, more curious — and more alive than I was at 40," the actor wrote. "Why? A partner who sees the best in me. Good lovin.'"
Photo credit: OConnor / AFF-USA.com / MEGA
#happy #mega
4 days ago
Geo Rutherford turned her fascination with unusual bodies of water into "Spooky Lake Month," a viral TikTok series featuring 186 lakes and rivers.
She traveled deep into the Peruvian Amazon to visit a boiling river where temperatures can reach 212°F.
Now a full-time artist and creator, Rutherford combines science, art and storytelling to explore the world's strangest waterways.
Geo Rutherford has spent the past seven years turning her fascination with strange bodies of water into an annual tradition.
The Wisconsin-based artist, educator and content creator is the founder of "Spooky Lake Month," a yearly TikTok series in which she explores unusual lakes and rivers, sharing the science, history and sometimes unsettling stories behind them with her followers. Now in its seventh season, the series has featured 186 different bodies of water.
#bodies #spooky #lake
She traveled deep into the Peruvian Amazon to visit a boiling river where temperatures can reach 212°F.
Now a full-time artist and creator, Rutherford combines science, art and storytelling to explore the world's strangest waterways.
Geo Rutherford has spent the past seven years turning her fascination with strange bodies of water into an annual tradition.
The Wisconsin-based artist, educator and content creator is the founder of "Spooky Lake Month," a yearly TikTok series in which she explores unusual lakes and rivers, sharing the science, history and sometimes unsettling stories behind them with her followers. Now in its seventh season, the series has featured 186 different bodies of water.
#bodies #spooky #lake
15 days ago
For the recently reported second quarter, PicS N.V. (NASDAQ:PICS) outperformed relative to its previous guidance across all profitability metrics. The total account base for the company went up to 70.4 million during the second quarter, showcasing a 10% jump from the prior year. Moving on to the bottom line figures, the adjusted earnings before tax, without factoring in costs ******* ociated with stock-based compensation came in at R$291 million for the quarter. This represented a 2.1% outperformance relative to the company's R$285 million guidance. Similarly, compared to the R$245 million projection, adjusted net income for the period actually stood 15.5% higher at R$283 million.
welcomia/Shutterstock.com
The second quarter concluded with strong financial and operating momentum for PicS. The company recorded a 9% annual and 2% sequential growth in its client base, which went up to 45.4 million active users. The total credit portfolio jumped to R$31.9 billion, exceeding management's guidance by 3%. This outperformance came due to a higher number of mature credit card cohorts, and accelerated origination within secured and partly secured categories. An additional factor that accounted for the credit portfolio growth was management's measured expansion into higher risk areas such as newer platform credit and private payroll lending.
Managerial revenue rose to R$3,730 million, topping guidance by 3.6%, and net interest income reached R$2,002 million, 5.4% above projections, boosted by growing credit income. Total cash in totaled R$136.4 billion, up 17% from a year earlier and 9% from the previous quarter, with customers bringing in an average of approximately R$45.4 billion to the platform each month. Total deposits climbed to R$35.8 billion, a 45% yearly jump and 10% quarterly rise.
Some concerns related to the company's loan portfolio emerged during the quarter. Non-performing loans more than 90 days overdue increased to 9.8% of the credit portfolio during the quarter, up 93 basis points sequentially. Stage 3 exposure, which includes a broader set of credit-impaired loans, reached 12.9% of the total credit portfolio.
#million #credit #quarter #Portfolio
welcomia/Shutterstock.com
The second quarter concluded with strong financial and operating momentum for PicS. The company recorded a 9% annual and 2% sequential growth in its client base, which went up to 45.4 million active users. The total credit portfolio jumped to R$31.9 billion, exceeding management's guidance by 3%. This outperformance came due to a higher number of mature credit card cohorts, and accelerated origination within secured and partly secured categories. An additional factor that accounted for the credit portfolio growth was management's measured expansion into higher risk areas such as newer platform credit and private payroll lending.
Managerial revenue rose to R$3,730 million, topping guidance by 3.6%, and net interest income reached R$2,002 million, 5.4% above projections, boosted by growing credit income. Total cash in totaled R$136.4 billion, up 17% from a year earlier and 9% from the previous quarter, with customers bringing in an average of approximately R$45.4 billion to the platform each month. Total deposits climbed to R$35.8 billion, a 45% yearly jump and 10% quarterly rise.
Some concerns related to the company's loan portfolio emerged during the quarter. Non-performing loans more than 90 days overdue increased to 9.8% of the credit portfolio during the quarter, up 93 basis points sequentially. Stage 3 exposure, which includes a broader set of credit-impaired loans, reached 12.9% of the total credit portfolio.
#million #credit #quarter #Portfolio
16 days ago
On September 18, Prudential Financial (NYSE:PRU) announced it will sell every share it holds in Alexforbes, a company listed on the Johannesburg Stock Exchange. Two buyers are splitting the stake. Alexforbes will repurchase roughly 372.8 million shares itself, and ARC AF Holdings will take about 74.1 million more. The package is worth about $185 million, a small number for a company managing $1.642 trillion. But the message matters more than the money. A plan Prudential laid out in August is now turning into signed agreements.
The logic is easy to follow. Prudential wants to operate in fewer places and put its money, people and attention where it thinks it can win for years. Andy Sullivan, the chief executive, says the aim is to lean harder on ***** et management, retirement and protection, and get those units working together more closely. David Legher, who leads emerging markets, called Alexforbes a successful investment, so this reads as a planned exit rather than a retreat from a problem.
The core business is giving management room to be choosy. On August 4, Prudential reported second-quarter net income of $985 million, up from $533 million a year earlier. That happened even though a charge from the yearly ***** umption update grew to $299 million from $134 million, so the underlying engine ran strong enough to absorb a bigger hit. The company also returned $743 million to shareholders in the quarter and held $4.2 billion in highly liquid ***** ets at the parent level. That does not look like a seller in a hurry.
Start with what has not happened yet. The deals are expected to close in the first half of 2027, and they still need Alexforbes shareholders to approve the buyback, along with regulatory sign-off. Until then, $185 million is an agreed price, not cash in the bank. Prudential also said New Veld's involvement continues before completion, so the company stays tied to the ***** et for now.
Then there is the size. Set against those trillions in ***** ets, this sale will not move results either way. Its value is strategic, and strategy takes years to judge. Prudential is giving up a foothold in a partnership it called important, and its remaining businesses have their own snags. Sales in Prudential of ***** an are suspended, and management said that weighed on international results even as earnings held up.
#august #money
The logic is easy to follow. Prudential wants to operate in fewer places and put its money, people and attention where it thinks it can win for years. Andy Sullivan, the chief executive, says the aim is to lean harder on ***** et management, retirement and protection, and get those units working together more closely. David Legher, who leads emerging markets, called Alexforbes a successful investment, so this reads as a planned exit rather than a retreat from a problem.
The core business is giving management room to be choosy. On August 4, Prudential reported second-quarter net income of $985 million, up from $533 million a year earlier. That happened even though a charge from the yearly ***** umption update grew to $299 million from $134 million, so the underlying engine ran strong enough to absorb a bigger hit. The company also returned $743 million to shareholders in the quarter and held $4.2 billion in highly liquid ***** ets at the parent level. That does not look like a seller in a hurry.
Start with what has not happened yet. The deals are expected to close in the first half of 2027, and they still need Alexforbes shareholders to approve the buyback, along with regulatory sign-off. Until then, $185 million is an agreed price, not cash in the bank. Prudential also said New Veld's involvement continues before completion, so the company stays tied to the ***** et for now.
Then there is the size. Set against those trillions in ***** ets, this sale will not move results either way. Its value is strategic, and strategy takes years to judge. Prudential is giving up a foothold in a partnership it called important, and its remaining businesses have their own snags. Sales in Prudential of ***** an are suspended, and management said that weighed on international results even as earnings held up.
#august #money
17 days ago
For the recently reported second quarter, PicS N.V. (NASDAQ:PICS) outperformed relative to its previous guidance across all profitability metrics. The total account base for the company went up to 70.4 million during the second quarter, showcasing a 10% jump from the prior year. Moving on to the bottom line figures, the adjusted earnings before tax, without factoring in costs ****** ociated with stock-based compensation came in at R$291 million for the quarter. This represented a 2.1% outperformance relative to the company's R$285 million guidance. Similarly, compared to the R$245 million projection, adjusted net income for the period actually stood 15.5% higher at R$283 million.
welcomia/Shutterstock.com
The second quarter concluded with strong financial and operating momentum for PicS. The company recorded a 9% annual and 2% sequential growth in its client base, which went up to 45.4 million active users. The total credit portfolio jumped to R$31.9 billion, exceeding management's guidance by 3%. This outperformance came due to a higher number of mature credit card cohorts, and accelerated origination within secured and partly secured categories. An additional factor that accounted for the credit portfolio growth was management's measured expansion into higher risk areas such as newer platform credit and private payroll lending.
Managerial revenue rose to R$3,730 million, topping guidance by 3.6%, and net interest income reached R$2,002 million, 5.4% above projections, boosted by growing credit income. Total cash in totaled R$136.4 billion, up 17% from a year earlier and 9% from the previous quarter, with customers bringing in an average of approximately R$45.4 billion to the platform each month. Total deposits climbed to R$35.8 billion, a 45% yearly jump and 10% quarterly rise.
Some concerns related to the company's loan portfolio emerged during the quarter. Non-performing loans more than 90 days overdue increased to 9.8% of the credit portfolio during the quarter, up 93 basis points sequentially. Stage 3 exposure, which includes a broader set of credit-impaired loans, reached 12.9% of the total credit portfolio.
#million #total
welcomia/Shutterstock.com
The second quarter concluded with strong financial and operating momentum for PicS. The company recorded a 9% annual and 2% sequential growth in its client base, which went up to 45.4 million active users. The total credit portfolio jumped to R$31.9 billion, exceeding management's guidance by 3%. This outperformance came due to a higher number of mature credit card cohorts, and accelerated origination within secured and partly secured categories. An additional factor that accounted for the credit portfolio growth was management's measured expansion into higher risk areas such as newer platform credit and private payroll lending.
Managerial revenue rose to R$3,730 million, topping guidance by 3.6%, and net interest income reached R$2,002 million, 5.4% above projections, boosted by growing credit income. Total cash in totaled R$136.4 billion, up 17% from a year earlier and 9% from the previous quarter, with customers bringing in an average of approximately R$45.4 billion to the platform each month. Total deposits climbed to R$35.8 billion, a 45% yearly jump and 10% quarterly rise.
Some concerns related to the company's loan portfolio emerged during the quarter. Non-performing loans more than 90 days overdue increased to 9.8% of the credit portfolio during the quarter, up 93 basis points sequentially. Stage 3 exposure, which includes a broader set of credit-impaired loans, reached 12.9% of the total credit portfolio.
#million #total
22 days ago
Emily Blunt and John Krasinski attended the US Open with their daughters Hazel, 12, and Violet, 10
The family has made attending the US Open an annual tradition, appearing at the tournament in recent years
Krasinski and Blunt have been candid about wanting to prioritize family time in recent interviews, and have shared that they often bringing their daughters to filming locations to stay together
John Krasinski, Emily Blunt and their daughters are continuing their annual family tradition of stopping by the US Open!
On Sunday, Sept. 13, the family of four made their yearly appearance at the 2026 US Open at the USTA's Billie Jean King National Tennis Center in New York City.
#krasinski #john #tradition
The family has made attending the US Open an annual tradition, appearing at the tournament in recent years
Krasinski and Blunt have been candid about wanting to prioritize family time in recent interviews, and have shared that they often bringing their daughters to filming locations to stay together
John Krasinski, Emily Blunt and their daughters are continuing their annual family tradition of stopping by the US Open!
On Sunday, Sept. 13, the family of four made their yearly appearance at the 2026 US Open at the USTA's Billie Jean King National Tennis Center in New York City.
#krasinski #john #tradition
24 days ago
GREEN BAY – It appears all the Green Bay Packers and tight end Tucker Kraft needed was a deadline to close the gap on their differences.
With the season a little more than 24 hours away, Kraft and the Packers agreed to terms on a four-year extension worth $75 million, including a $26.5 million signing bonus, a source confirmed Sept. 12. The deal could go as high as $92 million based on incentives and escalators
Kraft's deal falls just short of the yearly average of San Francisco tight end George Kittle's $19.1 million-a-year deal and does not include the same amount of guaranteed money. But the signing bonus is the highest of any tight end in the NFL.
This article originally appeared on Packers News: Packers, Tucker Kraft agree on 4-year contract extension on eve of season
#packers #kraft
With the season a little more than 24 hours away, Kraft and the Packers agreed to terms on a four-year extension worth $75 million, including a $26.5 million signing bonus, a source confirmed Sept. 12. The deal could go as high as $92 million based on incentives and escalators
Kraft's deal falls just short of the yearly average of San Francisco tight end George Kittle's $19.1 million-a-year deal and does not include the same amount of guaranteed money. But the signing bonus is the highest of any tight end in the NFL.
This article originally appeared on Packers News: Packers, Tucker Kraft agree on 4-year contract extension on eve of season
#packers #kraft
25 days ago
The Chicago Bears' 2026 season has finally arrived, and it couldn't come soon enough. Fresh off their 11-6 regular season in 2025 that saw them capture the NFC North and advance to the divisional round of the postseason, hopes are sky high for the Bears going into 2026, led by head coach Ben Johnson and quarterback Caleb Williams. And for good reason.
Williams broke through and ascended to become one of the upper-echelon quarterbacks in the league last season thanks to unreal throws and miraculous comebacks, while Johnson brought a tenacity to the locker room, along with his ever-evolving offensive mind, to build the Bears into a powerhouse. Now the Bears enter the year as contenders and aim to do something they haven't done in 20 years: Go to the postseason two years in a row.
As with any NFL season, things will ebb and flow each week. Legendary performances will be followed by clunky outings, and each game will be seen as a referendum on the entire year as it's dissected for six straight days. A lot is going to happen, and we're taking our best guesses as to what will take place in 2026. Here are our yearly bold predictions for the upcoming Chicago Bears season.
#season #year
Williams broke through and ascended to become one of the upper-echelon quarterbacks in the league last season thanks to unreal throws and miraculous comebacks, while Johnson brought a tenacity to the locker room, along with his ever-evolving offensive mind, to build the Bears into a powerhouse. Now the Bears enter the year as contenders and aim to do something they haven't done in 20 years: Go to the postseason two years in a row.
As with any NFL season, things will ebb and flow each week. Legendary performances will be followed by clunky outings, and each game will be seen as a referendum on the entire year as it's dissected for six straight days. A lot is going to happen, and we're taking our best guesses as to what will take place in 2026. Here are our yearly bold predictions for the upcoming Chicago Bears season.
#season #year
26 days ago
US stocks sank on Thursday morning as oil prices and Treasury yields continued to climb and investors ******* sed fresh wholesale inflation data.
The Dow Jones Industrial Average (^DJI) fell 0.5%, while the S&P 500 (^GSPC) fell 0.4%. The tech-heavy Nasdaq Composite (^IXIC) dropped 0.5%, with all three indexes deepening losses from the past three days.
Stocks have cooled this week as oil prices topped $105 per barrel after Iran targeted US Navy warships in the latest escalation in the Middle East conflict. The move higher in oil has helped support rising Treasury yields. The 10-year yield (^TNX) hit a three-year high on Wednesday after the Treasury Department announced it would buy up to $6 billion in longer-term debt.
President Trump said Wednesday that oil prices may not come down until after the midterm elections two months away. The ongoing US-Iran war and disruptions in the Strait of Hormuz have raised concerns that an energy shock could flow into broader inflation and all but force the Federal Reserve to raise interest rates.
On Thursday, wholesale inflation data showed producer prices rose on a monthly and yearly basis, largely in line with expectations, setting the stage for the government's consumer inflation report, due out Friday. The Producer Price Index rose 5.4% year-on-year, and 4.6% on a core basis.
#three
The Dow Jones Industrial Average (^DJI) fell 0.5%, while the S&P 500 (^GSPC) fell 0.4%. The tech-heavy Nasdaq Composite (^IXIC) dropped 0.5%, with all three indexes deepening losses from the past three days.
Stocks have cooled this week as oil prices topped $105 per barrel after Iran targeted US Navy warships in the latest escalation in the Middle East conflict. The move higher in oil has helped support rising Treasury yields. The 10-year yield (^TNX) hit a three-year high on Wednesday after the Treasury Department announced it would buy up to $6 billion in longer-term debt.
President Trump said Wednesday that oil prices may not come down until after the midterm elections two months away. The ongoing US-Iran war and disruptions in the Strait of Hormuz have raised concerns that an energy shock could flow into broader inflation and all but force the Federal Reserve to raise interest rates.
On Thursday, wholesale inflation data showed producer prices rose on a monthly and yearly basis, largely in line with expectations, setting the stage for the government's consumer inflation report, due out Friday. The Producer Price Index rose 5.4% year-on-year, and 4.6% on a core basis.
#three
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
28 days ago
The cornerback market rose again in the early morning hours Tuesday as the New England Patriots and star defensive back Christian Gonzalez agreed to a record-setting four-year, $135 million extension with $102 million guaranteed just ahead of the team's season opener, insider Jordan Schultz reported.
Gonzalez's $33.75 million yearly average sets the new top mark for cornerbacks, just ahead of the $33 million average-per-year contract fellow 2023 draftee and Seahawks cornerback Devon Witherspoon signed earlier this offseason.
Now, only one big-name cornerback contract dispute from the 2023 draft remains: the Steelers and Joey Porter Jr.'s "impasse."
Pittsburgh remains adamant in its policy of not negotiating with players during the regular season. And Porter hasn't closed the door on sitting out games if he isn't extended by Week 1. With the Steelers opening their season on Sunday, Sept. 13, the remaining window for an extension this offseason is rapidly shrinking — and the cornerback market keeps going up.
Porter is entering the final year of his rookie contract.
#cornerback #year #season
Gonzalez's $33.75 million yearly average sets the new top mark for cornerbacks, just ahead of the $33 million average-per-year contract fellow 2023 draftee and Seahawks cornerback Devon Witherspoon signed earlier this offseason.
Now, only one big-name cornerback contract dispute from the 2023 draft remains: the Steelers and Joey Porter Jr.'s "impasse."
Pittsburgh remains adamant in its policy of not negotiating with players during the regular season. And Porter hasn't closed the door on sitting out games if he isn't extended by Week 1. With the Steelers opening their season on Sunday, Sept. 13, the remaining window for an extension this offseason is rapidly shrinking — and the cornerback market keeps going up.
Porter is entering the final year of his rookie contract.
#cornerback #year #season
1 month ago
If it's strong capital appreciation that you're after, then Procter & Gamble (NYSE: PG) isn't the best investment candidate. Its shares are up just 67% in the past decade (as of Sept. 3), drastically underperforming the S&P 500 index.
But if you're seeking a blue chip dividend stock, then Procter & Gamble is hard to beat. Its dividend yield of nearly 3% is almost triple the benchmark average.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Here's how many shares of this company you'd need for $15,000 in yearly dividends.
Procter & Gamble currently pays an annual dividend of about $4.34 per share. This means you would have to own 3,456 shares to generate $15,000 in yearly passive income. Based on the stock price of $147.51, investors would be required to pay $510,000 to buy enough shares.
#NVIDIA #Stock #company
But if you're seeking a blue chip dividend stock, then Procter & Gamble is hard to beat. Its dividend yield of nearly 3% is almost triple the benchmark average.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Here's how many shares of this company you'd need for $15,000 in yearly dividends.
Procter & Gamble currently pays an annual dividend of about $4.34 per share. This means you would have to own 3,456 shares to generate $15,000 in yearly passive income. Based on the stock price of $147.51, investors would be required to pay $510,000 to buy enough shares.
#NVIDIA #Stock #company
1 month ago
JEPQ, DGRW, and JAAA together can convert a $250,000 life insurance lump sum into monthly deposits that replicate a working spouse's paycheck.
A $100,000 JEPQ allocation buys roughly 1,695 shares at $59, generating $8.46 annualized per share in monthly income with 18% yearly price gains.
JAAA's AAA-rated CLO holdings pay $2.70 per share annually with near-zero volatility, acting as the stable floor when equity markets drop.
Read More: Avoid these 13 retirement mistakes before they derail your future (sponsor)
Six weeks ago, the insurance company wired $250,000 into your checking account, and there it sits, earning almost nothing while you try to remember what day it is. That is fine. Life insurance death benefits are generally income-tax-free to the beneficiary, and no rule says grieving people have to make portfolio decisions on a schedule. When you are ready, though, three funds can turn that lump sum into a monthly deposit that behaves a lot like the paycheck your spouse used to bring home: JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ:JEPQ), WisdomTree U.S. Quality Dividend Growth Fund (NASDAQ:DGRW), and Janus Henderson AAA CLO ETF (NYSEARCA:JAAA).
#life
A $100,000 JEPQ allocation buys roughly 1,695 shares at $59, generating $8.46 annualized per share in monthly income with 18% yearly price gains.
JAAA's AAA-rated CLO holdings pay $2.70 per share annually with near-zero volatility, acting as the stable floor when equity markets drop.
Read More: Avoid these 13 retirement mistakes before they derail your future (sponsor)
Six weeks ago, the insurance company wired $250,000 into your checking account, and there it sits, earning almost nothing while you try to remember what day it is. That is fine. Life insurance death benefits are generally income-tax-free to the beneficiary, and no rule says grieving people have to make portfolio decisions on a schedule. When you are ready, though, three funds can turn that lump sum into a monthly deposit that behaves a lot like the paycheck your spouse used to bring home: JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ:JEPQ), WisdomTree U.S. Quality Dividend Growth Fund (NASDAQ:DGRW), and Janus Henderson AAA CLO ETF (NYSEARCA:JAAA).
#life
1 month ago
Good Friday morning everyone. Apple Cup week rolls on and we inch ever closer to the 1 PM Sunday kickoff. To quench your appetite, we have some Dots for you!
We have our yearly Staff Temperature Check here.
Andy Yamashita has a profile on one of the Big Ten's most underrated defenders, Alex McLaughlin.
Say Who, Say Pod sees Christian and Danny chatting with Coug superfan Adam Lewis.
Andrew Berg has the Big Ten Pick 6 for Week 1.
#Apple #sunday #staff
We have our yearly Staff Temperature Check here.
Andy Yamashita has a profile on one of the Big Ten's most underrated defenders, Alex McLaughlin.
Say Who, Say Pod sees Christian and Danny chatting with Coug superfan Adam Lewis.
Andrew Berg has the Big Ten Pick 6 for Week 1.
#Apple #sunday #staff
1 month ago
Julián Álvarez ended the summer window still on Atlético Madrid's books, but that outcome has settled almost nothing. Barcelona spent the entire market chasing the Argentine, Atlético publicly rejected the pursuit in increasingly hostile terms, and ******* nal explored an offer of their own while the whole thing threatened to boil over. The question now isn't whether the saga is over – it plainly isn't – but which of the three forces at play, Atlético's contractual leverage, Barcelona's valuation, or Álvarez's own stated preference, actually decides what happens next.
Álvarez himself gave the clearest signal of intent back in June, telling ESPN after Argentina's World Cup win over Austria that a transfer to Barcelona was the best thing for everyone and that he wanted to fulfil his dream. Those words were music to Joan Laporta's ears and poison to Atlético's dressing room. Everything that has followed, including deadline day passing without a deal, sits downstream of that one public admission.
Álvarez's Atlético contract runs until June 2030 and carries a release clause of around €500 million – a figure so far beyond market reality that it functions purely as leverage, not a genuine asking price. Barcelona say they made a €100 million bid; Atlético sources initially denied receiving any offer at all before later confirming one had arrived, structured across six yearly instalments and worth that same €100 million.
On July 30, with the dispute already curdling, Atlético reported Barcelona to the Spanish Football Federation over their pursuit of the player. No public update from the federation had followed by the time The Athletic's reconstruction of the saga was published. Álvarez remained at the Metropolitano when the window shut, and reports suggest he is expected to stay at Atlético at least until the January window reopens the conversation.
Before the summer even began, senior Atlético sources indicated the club would let Álvarez leave for €150 million provided a deal closed by July 20. That deadline passed with no agreement, and Atlético's position hardened dramatically. By late June, chief executive Miguel Ángel Gil Marín was drawing a line that had nothing to do with valuation gaps.
#window #federation #summer #nothing
Álvarez himself gave the clearest signal of intent back in June, telling ESPN after Argentina's World Cup win over Austria that a transfer to Barcelona was the best thing for everyone and that he wanted to fulfil his dream. Those words were music to Joan Laporta's ears and poison to Atlético's dressing room. Everything that has followed, including deadline day passing without a deal, sits downstream of that one public admission.
Álvarez's Atlético contract runs until June 2030 and carries a release clause of around €500 million – a figure so far beyond market reality that it functions purely as leverage, not a genuine asking price. Barcelona say they made a €100 million bid; Atlético sources initially denied receiving any offer at all before later confirming one had arrived, structured across six yearly instalments and worth that same €100 million.
On July 30, with the dispute already curdling, Atlético reported Barcelona to the Spanish Football Federation over their pursuit of the player. No public update from the federation had followed by the time The Athletic's reconstruction of the saga was published. Álvarez remained at the Metropolitano when the window shut, and reports suggest he is expected to stay at Atlético at least until the January window reopens the conversation.
Before the summer even began, senior Atlético sources indicated the club would let Álvarez leave for €150 million provided a deal closed by July 20. That deadline passed with no agreement, and Atlético's position hardened dramatically. By late June, chief executive Miguel Ángel Gil Marín was drawing a line that had nothing to do with valuation gaps.
#window #federation #summer #nothing
1 month ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Upgrade path: You could earn your security deposit back and upgrade to an unsecured Quicksilver card with responsible use.
Why we like this card for earning simple rewards: The Capital One Quicksilver Secured Cash Rewards has a straightforward earning rate of 1.5% cash back on all eligible purchases. That means you don't have to worry about different spending categories or rates, making it easy to use one card for everything.
Upgrade path: Your account is automatically evaluated yearly to see if you can upgrade to a Chase Freedom Unlimited card. To qualify for an upgrade, you must have:
An open Freedom Rise account
#back #earning #account
Upgrade path: You could earn your security deposit back and upgrade to an unsecured Quicksilver card with responsible use.
Why we like this card for earning simple rewards: The Capital One Quicksilver Secured Cash Rewards has a straightforward earning rate of 1.5% cash back on all eligible purchases. That means you don't have to worry about different spending categories or rates, making it easy to use one card for everything.
Upgrade path: Your account is automatically evaluated yearly to see if you can upgrade to a Chase Freedom Unlimited card. To qualify for an upgrade, you must have:
An open Freedom Rise account
#back #earning #account
1 month ago
Bitcoin (BTC) has managed to trim its yearly losses to just 11%, as traders jumped on board once again following the SEC's nod to the industry.
Although the initial euphoria has eased a bit, we still think the market's reaction could have put an end to the top crypto's bearish cycle.
The Treasury Department's decision to inject twice the amount it usually buys back in the bond market also signaled that the Trump administration is committed to pushing ******* et valuations to higher levels, with or without the Fed's support.
However, the rally may have hit a temporary ceiling, as ******* ysts once again see high odds that the U.S. central bank will raise rates in September.
Data from FedWatch shows that the probability of a 25 basis point increase during the next FOMC meeting shifted dramatically, jumping from 40% a week ago to 65% at the time of writing.
#once #Bitcoin #treasury #fedwatch
Although the initial euphoria has eased a bit, we still think the market's reaction could have put an end to the top crypto's bearish cycle.
The Treasury Department's decision to inject twice the amount it usually buys back in the bond market also signaled that the Trump administration is committed to pushing ******* et valuations to higher levels, with or without the Fed's support.
However, the rally may have hit a temporary ceiling, as ******* ysts once again see high odds that the U.S. central bank will raise rates in September.
Data from FedWatch shows that the probability of a 25 basis point increase during the next FOMC meeting shifted dramatically, jumping from 40% a week ago to 65% at the time of writing.
#once #Bitcoin #treasury #fedwatch
1 month ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Upgrade path: You could earn your security deposit back and upgrade to an unsecured Quicksilver card with responsible use.
Why we like this card for earning simple rewards: The Capital One Quicksilver Secured Cash Rewards has a straightforward earning rate of 1.5% cash back on all eligible purchases. That means you don't have to worry about different spending categories or rates, making it easy to use one card for everything.
Upgrade path: Your account is automatically evaluated yearly to see if you can upgrade to a Chase Freedom Unlimited card. To qualify for an upgrade, you must have:
An open Freedom Rise account
#freedom #rewards #back #earning
Upgrade path: You could earn your security deposit back and upgrade to an unsecured Quicksilver card with responsible use.
Why we like this card for earning simple rewards: The Capital One Quicksilver Secured Cash Rewards has a straightforward earning rate of 1.5% cash back on all eligible purchases. That means you don't have to worry about different spending categories or rates, making it easy to use one card for everything.
Upgrade path: Your account is automatically evaluated yearly to see if you can upgrade to a Chase Freedom Unlimited card. To qualify for an upgrade, you must have:
An open Freedom Rise account
#freedom #rewards #back #earning
1 month ago
Cardano (ADA) continues to underperform its peers this year, as on-chain metrics continue to indicate that this former crypto darling meets all the criteria of a "zombie chain."
The native token of this blockchain has booked a 40% loss in 2026, dramatically lagging its former peers like Ethereum (ETH) and Solana (SOL), both of which have managed to trim their yearly losses 17% as a result of the latest rally.
Market sentiment has improved in the past couple of weeks, as indicated by the Crypto Fear and Greed Index. This key gauge has jumped from a recent Neutral reading of 36 to 75 at the time of writing, indicating that investors are now in "Greed" mode.
Despite this shift in sentiment, ADA is not among the token that has managed to break above its 200-day exponential moving average (EMA), primarily as investors seem to be focusing on more mature projects that have demonstrated their real-world use cases.
This explains the huge performance gap between ADA and its peers. We can list a couple of red flags that may justify why market participants are shunning this token.
#greed #Crypto #market #managed
The native token of this blockchain has booked a 40% loss in 2026, dramatically lagging its former peers like Ethereum (ETH) and Solana (SOL), both of which have managed to trim their yearly losses 17% as a result of the latest rally.
Market sentiment has improved in the past couple of weeks, as indicated by the Crypto Fear and Greed Index. This key gauge has jumped from a recent Neutral reading of 36 to 75 at the time of writing, indicating that investors are now in "Greed" mode.
Despite this shift in sentiment, ADA is not among the token that has managed to break above its 200-day exponential moving average (EMA), primarily as investors seem to be focusing on more mature projects that have demonstrated their real-world use cases.
This explains the huge performance gap between ADA and its peers. We can list a couple of red flags that may justify why market participants are shunning this token.
#greed #Crypto #market #managed
1 month ago
Tech stocks were volatile on Monday as strengthening AI optimism from bullish Nvidia (NVDA) earnings last week clashed with increased odds of a Fed interest rate hike in September.
It's a momentous day for one company in particular — Apple (AAPL). Longtime CEO Tim Cook steps down on Sept. 1 and will hand the reins to senior vice president of hardware engineering John Ternus.
Cook was seen as a savvy operator, navigating the company through tariffs, supply chain snarls, and the launch of new products such as the Apple Watch and AirPods. He also quadrupled Apple's yearly revenue.
Elsewhere in tech, it was a mixed bag. Semiconductor stocks edged higher on the whole, while software stocks wavered, coming off a big week of decisively strong earnings. Several of the "Magnificent Seven" hyperscaler stocks, however, dropped as concerns about higher borrowing costs and capital expenditures weighed on shares.
OpenAI (OPAI.PVT) fought back against allegations that it stole trade secrets from Apple (AAPL), according to a new court filing published on Monday, as a legal battle between the two highly secretive tech firms heats up.
#stocks #Apple #Tech #company
It's a momentous day for one company in particular — Apple (AAPL). Longtime CEO Tim Cook steps down on Sept. 1 and will hand the reins to senior vice president of hardware engineering John Ternus.
Cook was seen as a savvy operator, navigating the company through tariffs, supply chain snarls, and the launch of new products such as the Apple Watch and AirPods. He also quadrupled Apple's yearly revenue.
Elsewhere in tech, it was a mixed bag. Semiconductor stocks edged higher on the whole, while software stocks wavered, coming off a big week of decisively strong earnings. Several of the "Magnificent Seven" hyperscaler stocks, however, dropped as concerns about higher borrowing costs and capital expenditures weighed on shares.
OpenAI (OPAI.PVT) fought back against allegations that it stole trade secrets from Apple (AAPL), according to a new court filing published on Monday, as a legal battle between the two highly secretive tech firms heats up.
#stocks #Apple #Tech #company
1 month ago
GOLF
Girls
Middleburg 209, Keystone Heights 260
Course: Eagle Landing (Middleburg).
The USA TODAY Network is kicking off the high school sports rush with an opportunity for Florida Times-Union readers to get a discount on a yearly subscription to the NFHS Network.
#golf #keystone #eagle #today
Girls
Middleburg 209, Keystone Heights 260
Course: Eagle Landing (Middleburg).
The USA TODAY Network is kicking off the high school sports rush with an opportunity for Florida Times-Union readers to get a discount on a yearly subscription to the NFHS Network.
#golf #keystone #eagle #today
1 month ago
The very first developments of the Met Gala 2027 are here! (Sorry if you were still getting over Beyoncé and Blue Ivy shutting down the red carpet together this year!)
Every year as May rolls around, fashion enthusiasts all over the world shift their attention to the Met Gala. The extravaganza takes over the Metropolitan Museum of Art's famed stairs for one night, turning every viewer at home into a fashion critic.
However, though many tune in for the theatrics, the Met Gala is actually a yearly fundraiser for the museum's Costume Institute, which each spring hosts a different exhibition that informs the night's fashion shenanigans. And that exhibition is going through changes for 2027, with its honoree pulling out after the announcement.
Given how buzzy it is, it's totally understandable that there's already excitement for next year. If you want to know everything about the guiding thread for the Met Gala 2027, we've gathered everything we know so far below.
#every #exhibition #everything
Every year as May rolls around, fashion enthusiasts all over the world shift their attention to the Met Gala. The extravaganza takes over the Metropolitan Museum of Art's famed stairs for one night, turning every viewer at home into a fashion critic.
However, though many tune in for the theatrics, the Met Gala is actually a yearly fundraiser for the museum's Costume Institute, which each spring hosts a different exhibition that informs the night's fashion shenanigans. And that exhibition is going through changes for 2027, with its honoree pulling out after the announcement.
Given how buzzy it is, it's totally understandable that there's already excitement for next year. If you want to know everything about the guiding thread for the Met Gala 2027, we've gathered everything we know so far below.
#every #exhibition #everything
1 month ago
Companies worried for years about whether an employee's password had been stolen.
Now they have to worry about AI "workers," too.
Okta (OKTA) reported fiscal second-quarter revenue of $805 million, up 11%, while subscription revenue reached $793 million, up 12%. Remaining performance obligations increased 17% to nearly $4.86 billion.
The company boosted its yearly outlook as organizations increasingly face a category of identity that was virtually nonexistent in mainstream commercial IT only a few years ago: autonomous AI agents.
"Every agent needs a trusted identity and clear controls over what it can access and do," CEO Todd McKinnon said.
#okta #years #every #mckinnon
Now they have to worry about AI "workers," too.
Okta (OKTA) reported fiscal second-quarter revenue of $805 million, up 11%, while subscription revenue reached $793 million, up 12%. Remaining performance obligations increased 17% to nearly $4.86 billion.
The company boosted its yearly outlook as organizations increasingly face a category of identity that was virtually nonexistent in mainstream commercial IT only a few years ago: autonomous AI agents.
"Every agent needs a trusted identity and clear controls over what it can access and do," CEO Todd McKinnon said.
#okta #years #every #mckinnon
1 month ago
Companies worried for years about whether an employee's password had been stolen.
Now they have to worry about AI "workers," too.
Okta (OKTA) reported fiscal second-quarter revenue of $805 million, up 11%, while subscription revenue reached $793 million, up 12%. Remaining performance obligations increased 17% to nearly $4.86 billion.
The company boosted its yearly outlook as organizations increasingly face a category of identity that was virtually nonexistent in mainstream commercial IT only a few years ago: autonomous AI agents.
"Every agent needs a trusted identity and clear controls over what it can access and do," CEO Todd McKinnon said.
#okta #million #identity #remaining
Now they have to worry about AI "workers," too.
Okta (OKTA) reported fiscal second-quarter revenue of $805 million, up 11%, while subscription revenue reached $793 million, up 12%. Remaining performance obligations increased 17% to nearly $4.86 billion.
The company boosted its yearly outlook as organizations increasingly face a category of identity that was virtually nonexistent in mainstream commercial IT only a few years ago: autonomous AI agents.
"Every agent needs a trusted identity and clear controls over what it can access and do," CEO Todd McKinnon said.
#okta #million #identity #remaining
1 month ago
If you're looking for a well-proven dividend stock, consumer goods name Procter & Gamble (NYSE: PG) is about as good as they come, with 70 consecutive years of annual dividend hikes to its credit. Indeed, only one other company has a longer track record of uninterrupted yearly dividend increases. That streak isn't apt to end anytime soon, if ever.
But reliable dividend growth is only half the story. How much are income investors actually making with their positions in P&G?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Procter & Gamble's forward-looking dividend yield currently stands at 3%, based on a quarterly payment of $1.0885 per share. A $25,000 position in the stock -- about 172 shares -- would produce just over $187 in dividend income per quarter, or just under $750 per year. That's not earth-shattering, but it's not bad either.
But those numbers arguably understate the total long-term potential that Procter & Gamble offers to patient investors. This company also boasts one of the better rates of dividend growth among blue chip dividend payers. Over the past 10 completed fiscal years, Procter's annual dividend payout has grown from $2.66 to $4.26 per share, and is currently running at an annualized pace of $4.35 per share. That's annualized growth of right around 4.8%, easily outpacing inflation as well as most other Dividend Kings' payment increase rates.
#Dividend #signal #Growth #flashing
But reliable dividend growth is only half the story. How much are income investors actually making with their positions in P&G?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Procter & Gamble's forward-looking dividend yield currently stands at 3%, based on a quarterly payment of $1.0885 per share. A $25,000 position in the stock -- about 172 shares -- would produce just over $187 in dividend income per quarter, or just under $750 per year. That's not earth-shattering, but it's not bad either.
But those numbers arguably understate the total long-term potential that Procter & Gamble offers to patient investors. This company also boasts one of the better rates of dividend growth among blue chip dividend payers. Over the past 10 completed fiscal years, Procter's annual dividend payout has grown from $2.66 to $4.26 per share, and is currently running at an annualized pace of $4.35 per share. That's annualized growth of right around 4.8%, easily outpacing inflation as well as most other Dividend Kings' payment increase rates.
#Dividend #signal #Growth #flashing
1 month ago
Even after 25-plus years in the fantasy industry and much success in high-stakes leagues, there inevitably comes a day early in each season in which I wish I had taken the time to write out the bull and bear case for each player likely to get drafted. Such a thing takes a lot of time, which is part of the reason why it is so hard to find such a thing on any fantasy website.
With my Big Board rankings being released as we speak, now feels like the perfect time to conduct such an exercise. Along with several members of my talented writing team here at The Huddle (Steve Hungarter, Harley Schultz, HC Green, Kevin Tompkins), we present the first edition of what I hope becomes a yearly tradition: detailed **** ysis as to why a player will live up to his Big Board ranking and why he may not.
Note: Rankings are based on the release of the 8/21 version of the Big Board. Because of the amount of time it will take to update each of the five articles in this series each time there is a change in the rankings, there are no plans to update the rankings next to each player in this story. If new players are added to the Big Board over the final few weeks of the preseason, I will add a sixth installment at the end of the series.
The links to all five stories (and the 150 players we discuss) are below:
1-30 | 31-60| 61-90 | 91-120 | 121-150
#time #player
With my Big Board rankings being released as we speak, now feels like the perfect time to conduct such an exercise. Along with several members of my talented writing team here at The Huddle (Steve Hungarter, Harley Schultz, HC Green, Kevin Tompkins), we present the first edition of what I hope becomes a yearly tradition: detailed **** ysis as to why a player will live up to his Big Board ranking and why he may not.
Note: Rankings are based on the release of the 8/21 version of the Big Board. Because of the amount of time it will take to update each of the five articles in this series each time there is a change in the rankings, there are no plans to update the rankings next to each player in this story. If new players are added to the Big Board over the final few weeks of the preseason, I will add a sixth installment at the end of the series.
The links to all five stories (and the 150 players we discuss) are below:
1-30 | 31-60| 61-90 | 91-120 | 121-150
#time #player
1 month ago
KO and JNJ have raised dividends for decades, but their low yields mean replacing $120K in salary demands $3M or more in capital.
Realty Income and Verizon yield 5% to 6%, cutting required capital to $2M, but dividend growth in this band slows to pennies annually.
A 12% yield that never grows from a fund losing 3% NAV yearly leaves both buying power and principal noticeably smaller after a decade.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
Consider a $120,000 salary, which sits near the ceiling of median household income in expensive metros and is roughly what senior engineers, experienced nurse practitioners, and mid-career attorneys pull down before taxes. Replacing that with dividend income instead of a regular paycheck is the goal that quietly drives most late-career portfolio decisions, and the amount of capital required swings by millions depending on the yield you are willing to accept.
#income #Dividend #Career
Realty Income and Verizon yield 5% to 6%, cutting required capital to $2M, but dividend growth in this band slows to pennies annually.
A 12% yield that never grows from a fund losing 3% NAV yearly leaves both buying power and principal noticeably smaller after a decade.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
Consider a $120,000 salary, which sits near the ceiling of median household income in expensive metros and is roughly what senior engineers, experienced nurse practitioners, and mid-career attorneys pull down before taxes. Replacing that with dividend income instead of a regular paycheck is the goal that quietly drives most late-career portfolio decisions, and the amount of capital required swings by millions depending on the yield you are willing to accept.
#income #Dividend #Career
1 month ago
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion.
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#gild #increased
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#gild #increased
1 month ago
The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday's blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer's (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in one therapeutic area. For investors, this is ultimately a choice between an unfinished turnaround and a stronger growth story still searching for greater breadth.
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.
#NYSE #million #gild
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.
#NYSE #million #gild
1 month ago
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion.
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#product
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#product
